InterMune wins FDA OK for lung-scarring disease drug at center of Roche deal

October 15, 2014 10:14 PM

4 0

InterMune wins FDA OK for lung-scarring disease drug at center of Roche deal

A treatment for a fatal lung-scarring disease — the center of an $8.3 billion buyout of a Peninsula company by drug giant Roche — won regulatory approval Wednesday.

The drug, called Esbriet, was developed by InterMune Inc. of Brisbane to treat idiopathic pulmonary fibrosis, a disease where scar tissue builds up in the lungs and makes it difficult to breathe. The cause of IPF is unknown, and there had been no Food and Drug Administration-approved drugs.

Also read: Ohio State attacker was angry about treatment of Muslims, official says

Read more

To category page

Loading...